Nanoparticles targeted to cancer cells by antibodies cannot achieve enough specificity to kill drug-resistant cancer cells while sparing normal cells, but can achieve enough specificity to produce nanobubbles only in cancer cells, so the drug only enters cancer cells.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.